You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Risk-based Patient Monitoring for Pediatric Cardiac Patients

    SBC: Etiometry Inc.            Topic: NHLBI

    AbstractDuring a successful Phase 2 effort, Etiometry collaborated with multiple world-class pediatric centers to develop, validate, and deploy novel analytics that combine multiple physiologic data streams into a probabilistic assessment of inadequate oxygen delivery to critically ill patients. The analytics were integrated into the Etiometry Platform with the goal of improving physician situatio ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Definition of pharmacodynamic biomarkers for juvenile dermatomyositis for clinical trials

    SBC: REVERAGEN BIOPHARMA, INC.            Topic: NIAMS

    Definition of pharmacodynamic biomarkers for juvenile dermatomyositis for clinical trials Juvenile dermatomyositisJDMis a rare disease with an incidence rate in the United States ofchildren per million per yearMendez et aland is the most commonmember of the group of inflammatory juvenile myopathiesJMChildren with JDM display a classic heliotrope rashGottronandapos s papulessymmetrical proximal mus ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Establishing a biomarker framework for feasibility studies of vamorolone in vasculitis

    SBC: REVERAGEN BIOPHARMA, INC.            Topic: NIAMS

    Project Summary Abstract Antineutrophil cytoplasmic antibodyANCAassociated vasculitisAAVis a group of rare organ and lifethreatening multisystem diseases involving inflammation and destruction of small blood arteriesAAV appears mediated by neutrophilsbut the mechanisms underlying the neutrophil infiltration and activation are poorly understoodThe disease is treated with glucocorticoids and other a ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer

    SBC: PRIVO TECHNOLOGIES, LLC            Topic: NCI

    Preceding Award: NCI Award 1R44CA192875-02 Project Summary: According to the Oral Cancer Foundation, about 50,000 people in the US will be newly diagnosed with oral cancer (OC) in 2017, causing 9,700 deaths[1]. OC is a severely neglected orphan disease with a lack of significant treatment advances in 4 decades[1]. Historically, OC has been present in heavy smokers and drinkers. However, more recen ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Interactive Training in Emergency Operations for the Response Community

    SBC: GRYPHON SCIENTIFIC, LLC            Topic: NIEHS

    In this competitive revision Phase II SBIR, Gryphon Scientific proposes to expand the scope of the ongoing project to support the urgent need to develop and deploy training for two populations of citizen responders at risk of coronavirus exposure. The ongoing Phase II SBIR project focuses on training responders, including Community Emergency Response Teams (CERT) and the Medical Reserve Corps (MRC ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Advancing a novel portable detection method for cannabis intoxication

    SBC: Brain Solutions, LLC            Topic: NIDA

    TBD

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Novel genotoxicity assay incorporating the toxicogenomics biomarker TGx-28.65 with a direct digital counting

    SBC: AMELIA TECHNOLOGIES LLC            Topic: NIEHS

    Regulatory agencies including EPAFDAECHAand EMA require thorough assessment of the health effects of chemicals present in the environment and marketplaceInterpretation of positive genotoxicity findings using the current standard in vitro testing battery is a major challenge to both industry and regulatory agenciesThese tests have high sensitivitybut suffer from low specificityleading to high rates ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Surfactant-vesicle based gonorrhea vaccine

    SBC: SD NANOSCIENCES, INC            Topic: NIAID

    Vaccination is the most cost effective method for controlling and eradicating infectious diseasesIts significant impact on human health is exemplified by the eradication of smallpox and the elimination of poliomyelitis from most of the world and measles in many developed countriesWith the emergence of ceftriaxone resistant Neisseria gonorrhoeaeit is imperative that we generate a vaccine for this d ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus

    SBC: CELDARA MEDICAL, LLC            Topic: NIAID

    PROJECT SUMMARY The filovirusesfamily Filoviridaecomprising five ebolavirusesa cuevavirusand two Marburg virusesare negative strand RNA viruses that cause severe hemorrhagic fever with up tohuman case fatality rateTheepidemic in Western Africacaused by the Zaire ebolavirusEBOVspecies demonstrated the potential for these viruses to cause dire health emergencies of global scopeand highlighted the ne ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Development Of Novel Diabetes Therapies Based On Neutralizing FSTL3 Activity

    SBC: Fairbanks Pharmaceuticals Inc            Topic: 200

    Both typeand typediabetes involve loss of insulin producing pancreaticcells resulting in inadequate insulin secretion to control blood glucoseand ultimately requiring daily insulin injections to avoid the constellation of life threatening complications that arise from long term hyperglycemiaWhile transplantation of cadaveric pancreatic islets that containcells has been successful for treating a sm ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government